314 related articles for article (PubMed ID: 27560285)
1. Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents.
Li G; Huan Y; Yuan B; Wang J; Jiang Q; Lin Z; Shen Z; Huang H
Eur J Med Chem; 2016 Nov; 124():103-116. PubMed ID: 27560285
[TBL] [Abstract][Full Text] [Related]
2. The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119.
Li G; Meng B; Yuan B; Huan Y; Zhou T; Jiang Q; Lei L; Sheng L; Wang W; Gong N; Lu Y; Ma C; Li Y; Shen Z; Huang H
Eur J Med Chem; 2020 Feb; 188():112017. PubMed ID: 31926470
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of tetrahydropyridopyrimidine derivatives as dual GPR119 and DPP-4 modulators.
Fang Y; Zhang S; Wu W; Liu Y; Yang J; Li Y; Li M; Dong H; Jin Y; Liu R; Yang Z
Bioorg Chem; 2020 Jan; 94():103390. PubMed ID: 31662212
[TBL] [Abstract][Full Text] [Related]
4. Rapid generation of novel benzoic acid-based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: Scaffold-hopping and prodrug study.
Li Q; Meng L; Zhou S; Deng X; Wang N; Ji Y; Peng Y; Xing J; Yao G
Eur J Med Chem; 2019 Oct; 180():509-523. PubMed ID: 31336309
[TBL] [Abstract][Full Text] [Related]
5. Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors.
Deng X; Han L; Zhou J; Zhang H; Li Q
Bioorg Chem; 2017 Dec; 75():357-367. PubMed ID: 29096096
[TBL] [Abstract][Full Text] [Related]
6. Scaffold-based design of xanthine as highly potent inhibitors of DPP-IV for improving glucose homeostasis in DIO mice.
Ran Y; Pei H; Xie C; Ma L; Wu Y; Lei K; Shao M; Tang M; Xiang M; Peng A; Wei Y; Chen L
Mol Divers; 2015 May; 19(2):333-46. PubMed ID: 25672287
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors.
Li Q; Han L; Zhang B; Zhou J; Zhang H
Org Biomol Chem; 2016 Oct; 14(40):9598-9611. PubMed ID: 27714283
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors.
Li Q; Zhou M; Han L; Cao Q; Wang X; Zhao L; Zhou J; Zhang H
Chem Biol Drug Des; 2015 Oct; 86(4):849-56. PubMed ID: 25787859
[TBL] [Abstract][Full Text] [Related]
9. Surrogating and redirection of pyrazolo[1,5-a]pyrimidin-7(4H)-one core, a novel class of potent and selective DPP-4 inhibitors.
Deng X; Shen J; Zhu H; Xiao J; Sun R; Xie F; Lam C; Wang J; Qiao Y; Tavallaie MS; Hu Y; Du Y; Li J; Fu L; Jiang F
Bioorg Med Chem; 2018 Feb; 26(4):903-912. PubMed ID: 29373269
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors.
Patel BD; Bhadada SV; Ghate MD
Bioorg Chem; 2017 Jun; 72():345-358. PubMed ID: 28302310
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of xanthine derivatives on dipeptidyl peptidase 4.
Lin K; Cai Z; Wang F; Zhang W; Zhou W
Chem Pharm Bull (Tokyo); 2013; 61(4):477-82. PubMed ID: 23358258
[TBL] [Abstract][Full Text] [Related]
12. Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation.
Meduru H; Wang YT; Tsai JJ; Chen YC
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304951
[TBL] [Abstract][Full Text] [Related]
13. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
[TBL] [Abstract][Full Text] [Related]
14. Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization.
Xie H; Zeng L; Zeng S; Lu X; Zhang G; Zhao X; Cheng N; Tu Z; Li Z; Xu H; Yang L; Zhang X; Huang M; Zhao J; Hu W
Eur J Med Chem; 2012 Jun; 52():205-12. PubMed ID: 22475866
[TBL] [Abstract][Full Text] [Related]
15. Structure based virtual screening of MDPI database: discovery of structurally diverse and novel DPP-IV inhibitors.
Tanwar O; Tanwar L; Shaquiquzzaman M; Alam MM; Akhter M
Bioorg Med Chem Lett; 2014 Aug; 24(15):3447-51. PubMed ID: 24948564
[TBL] [Abstract][Full Text] [Related]
16. 3D QSAR and docking study of gliptin derivatives as DPP-IV inhibitors.
Agrawal R; Jain P; Dikshit SN; Bahare RS
Comb Chem High Throughput Screen; 2013 May; 16(4):249-73. PubMed ID: 23305140
[TBL] [Abstract][Full Text] [Related]
17. Ephedrine as a lead compound for the development of new DPP-IV inhibitors.
Ojeda-Montes MJ; Ardid-Ruiz A; Tomás-Hernández S; Gimeno A; Cereto-Massagué A; Beltrán-Debón R; Mulero M; Garcia-Vallvé S; Pujadas G; Valls C
Future Med Chem; 2017 Dec; 9(18):2129-2146. PubMed ID: 29172693
[TBL] [Abstract][Full Text] [Related]
18.
Martins MCMR; Pantaleao SQ; de Oliveira Almeida M; Weber KC; Honorio KM
Med Chem; 2021; 17(3):247-263. PubMed ID: 31995015
[TBL] [Abstract][Full Text] [Related]
19. Natural phenolic compounds potentiate hypoglycemia via inhibition of Dipeptidyl peptidase IV.
Huang PK; Lin SR; Chang CH; Tsai MJ; Lee DN; Weng CF
Sci Rep; 2019 Oct; 9(1):15585. PubMed ID: 31666589
[TBL] [Abstract][Full Text] [Related]
20. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
Maezaki H; Banno Y; Miyamoto Y; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Sasaki M; Tsubotani S; Tani A; Funami M; Yamamoto Y; Tawada M; Aertgeerts K; Yano J; Oi S
Bioorg Med Chem; 2011 Aug; 19(15):4482-98. PubMed ID: 21741847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
